Press releases

August 9, 2022 Invitae Reports $136.6 Million in Revenue in Second Quarter of 2022
— Continued to execute towards operational excellence with portfolio optimization, broad cost controls and cash management — — Recently announced realignment plan is expected to extend the company's cash runway to the end of 2024; Maintain financial guidance — Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Tim e — Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the second quarter ended June 30, 2022. "In the second quarter, we are pleased with our progress towards achieving operational excellence, as demonstrated by the improvements in several key metrics focusing on non-GAAP gross margin, operating expense, and cash burn trajectory, both on a year-over-year and quarter-over-quarter basis. These numbers reflected positive results based on the initiatives that we have been implementing," said Ken Knight, president and chief executive officer of Invitae. "We recently announced our strategic
Read more
August 8, 2022 New NCCN Colorectal Cancer Guidelines Recommend Genetic Testing for All Diagnosed Patients
As a result of recent research revealing that a significant number of colorectal cancer patients with actionable variants are missed under previous genetic testing guidelines, the National Comprehensive Cancer Network (NCCN) announced new guidelines calling for testing to be available to all patients diagnosed with colorectal cancer. Specifically, NCCN recommended that germline multigene panel testing should be offered to all individuals with CRC age <50 and be considered for all others, particularly for, but not restricted to, those with evidence of mismatch repair in their tumor or suggestive family history. These new recommendations expand the current testing criteria, which limited testing to certain age groups and types of cancer. The new NCCN guidelines follow recent landmark studies published in JAMA Oncology and Clinical Gastroenterology and Hepatology by Invitae and Mayo Clinic supporting universal genetic testing for all cancer patients, regardless of cancer type, age,
Read more
August 2, 2022 Invitae to Announce Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2022 financial results on Tuesday, August 9, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To access the conference call, please register at the link below: https://events.q4inc.com/attendee/937240483 Upon registering, each participant will be provided with call details and access codes. The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of
Read more
July 18, 2022 Invitae Announces Strategic Business Realignment to Accelerate Its Path to Positive Cash Flow and Realize Full Potential of Industry-Leading Genetics Testing Platform
— Exiting non-core businesses and geographies to prioritize higher-margin business initiatives — — Expects to deliver approximately $326 million in non-GAAP annualized cost savings in 2023 — — Provides preliminary revenue and gross margin ranges for the second quarter of 2022; amends full-year 2022 financial guidance — — Conference call and webcast today at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time — Invitae (NYSE: NVTA), a leading medical genetics company, today announced a comprehensive plan to realize the full potential of its industry-leading genetics platform. The plan introduces a significant realignment of the company's operations in support of business lines and geographies that generate sustainable margins, provide the best return to fuel future investment and accelerate the company's path to positive cash flow. The plan further helps ensure Invitae remains at the forefront of innovation and advancements in genomics by allocating resources towards the company's core
Read more
July 18, 2022 Invitae Announces Leadership Transition
— COO Kenneth D. Knight named CEO succeeding Sean George; Dr. George to continue as member of Board of Directors — Invitae (NYSE: NVTA), a leading medical genetics company, today announced executive leadership and Board changes to help ensure the company realizes the full potential of its industry-leading genetics testing platform and delivers tangible and sustainable value for stockholders. Specifically, Kenneth D. Knight, who has served as Invitae's chief operating officer since 2020, is succeeding Sean George, Ph.D., as CEO and is joining the Board of Directors. Additionally, Randy Scott, Ph.D., Invitae's co-founder, former CEO from 2012 to 2017, and former executive chairman from 2017 to 2019, is returning to the company as chairman of the Board. Eric Aguiar, who has served as Invitae's independent chairman since 2019 and a member of the Board since 2010, is now serving as lead independent director. The changes are effective immediately. Dr. George, co-founder and CEO of Invitae
Read more
June 6, 2022 Aussies Must Rise To Genetics Challenge As New Analysis Reveals Raw Reality For Cancer Families
Leading patient organisation, Pink Hope, launches an advocacy collaboration to help Australian families get the answers they need sooner, as new analysis highlights the potential barriers and delays to genetic testing across the nation Families failed by red tape. A new analysis from Invitae, a leading medical genetics company, reveals that up to two-thirds of Australian breast cancer patients with high risk, hereditary gene variants (such as BRCA) would not qualify for genetic testing due to the nation’s eligibility criteria and would be unable to access what can be life-changing knowledge 1 . Consequences of delayed testing: For those who do receive a referral for genetic testing in NSW, they can face over a 12 month, or longer wait time3 – during which they and their family members could develop cancer, have their cancer progress, or not get access to personalised treatment that could increase survival. A new genetics advocacy collaboration launches today with the aim to educate
Read more
May 26, 2022 New Research Demonstrates Genetic Information Can Transform Cancer Care, Guidelines Remain a Barrier to Patient Access
Invitae (NYSE: NVTA), a leading medical genetics company, today announced eight studies to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago from June 3-7, 2022. While the research covers a variety of cancer types, stages and patient demographics, all of the data underscore the importance of universal genetic testing to improve health outcomes for all cancer patients. Inherited genes impact risk for developing melanoma Melanoma—the most frequent cause of skin cancer-related deaths—is often perceived as a cancer caused by environmental factors. While sun exposure plays a role in most melanoma tumors, a new, first-of-its-kind study by Cleveland Clinic and Invitae found that genetics also play a critical role in the likelihood of developing melanoma. In fact, the study found that 15% of individuals with melanoma have inherited variants in a variety of genes associated with cancer predisposition syndromes, demonstrating multiple potential
Read more
May 19, 2022 Invitae Launches Expanded Pharmacogenomics Panel and Specialized Mental Health Panel
Invitae (NYSE: NVTA), a leading medical genetics company, today announced the commercial availability of the expanded Invitae Pharmacogenomics (PGx) Panel which includes the specialized Invitae Pharmacogenomics Mental Health Panel and access to a clinical decision support tool (CDST). With this launch, Invitae now has one of the most comprehensive commercially available PGx panels in the industry. In addition to mental health medications, the panel aligns with PGx-specific guidelines and published evidence that affects hundreds of commonly used medications, including frequently prescribed medications for high-risk patients in primary care, cardiology, endocrinology, pain management and oncology. Nearly one in four patients has been prescribed medications for which they are predicted to have an atypical response due to their genetics. Given the compelling evidence that patient care can benefit from this information, PGx testing is poised to become the standard of care across all
Read more
May 3, 2022 Invitae Reports $123.7 Million in Revenue in First Quarter of 2022 and Extends Cash Runway
— Executing toward 2022 plan, generating near 20% revenue growth, with $885 million in ending cash* , an annualized burn reduction of greater than $100 million — — Broad OPEX controls and portfolio optimization to decrease spend, extend runway through 2023— — Company lays out path for continued industry-leading growth while achieving positive operating cash flow by end of 2025 — — Technology Day investor forum to be held week of July 11, roadmap for the creation of a new category in healthcare — — Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time — , a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2022. "The power of personal health information, enabled by a new breed of patient and clinician workflow tools, further combined with real world data, is an immense opportunity to shape the future of medicine. And while the proof points supporting our model of enabling a new era
Read more
April 20, 2022 Invitae to Announce First Quarter 2022 Financial Results on Tuesday, May 3, 2022
  Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2022 financial results on Tuesday, May 3, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To access the conference call, please register at the link below:
https://www.incommglobalevents.com/registration/q4inc/10749/invitae/#39s-first-quarter-2022-financial-results-conference-call/ Upon registering, each participant will be provided with call details and access codes. The live webcast of the call and slide deck may be accessed here  or by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose
Read more
April 4, 2022 Invitae Introduces First Comprehensive Genetic Test Suite for Neurodevelopmental Disorders
Invitae (NYSE: NVTA), a leading medical genetics company, today announced the full commercial launch of its Neurodevelopmental Disorders (NDD) package to deliver a robust testing suite that can deliver actionable genetic insights to inform treatment plans for children with developmental disabilities. Invitae is the first to offer this particular suite of tests to clinicians and patients in an easily accessible format. The package includes chromosomal microarray analysis, analysis for fragile X-related disorders, and a next-generation-sequencing panel of 200+ genes in which variants are associated with neurodevelopmental disorders. The gene panel can detect sequence variants as well as full or partial gene deletions and duplications (i.e. intragenic copy number variants) that a chromosomal microarray analysis (CMA) alone may not detect. The comprehensive package provides reports for all three tests and can help provide clarity on the genetic etiology and root cause of these complex and
Read more
March 29, 2022 Introducing Invitae Digital Health--A Personalized Health Management Platform That Leverages Genomic Insights to Inform Health Decisions for Patients and Clinicians
Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of Invitae Digital Health—a connected digital health platform that informs health decisions through actionable genomic insights for patients and clinicians. With Invitae Digital Health, healthcare providers and health systems engage with a single, seamless platform that integrates important health data throughout each patient's lifetime. Rooted in genetic insights and scalable at the population level, it will enable a holistic approach to personalized health management for individuals throughout their health journey. Ushering in a new era of proactive healthcare With 19.3 million new cases of cancer worldwide in 2020, 420 million cases of cardiovascular disease 2 , 8 million children born with a serious genetic condition each year worldwide 3 , and 99% of people with genetic variation that can impact drug response 4 , the potential impact of genetics on mainstream healthcare is profound. A modular
Read more
March 17, 2022 Invitae Launches Full Access to its Liquid-Based Personalized Cancer Monitoring Platform to Help Detect Disease Earlier
Invitae (NYSE: NVTA), a leading medical genetics company, today announced full access to its Personalized Cancer Monitoring (PCM TM ) platform to help detect minimal or molecular residual disease (MRD) in patients with solid tumors. Invitae PCM uses a novel set of personalized assays based on a patient's tumor to detect circulating tumor DNA (ctDNA) in blood, offering the ability to perform risk stratification, response assessment to treatment and detection of cancer recurrence, based on recent studies. "Relapse risk stratification is a clinical need for many patients undergoing treatment for solid tumors and is best served by up-to-date molecular tools to complement and improve upon the standard of care methods for recurrence detection," said Robert Nussbaum, M.D., chief medical officer, Invitae. "The PCM platform complements current monitoring methods, and has the ability to determine a cancer therapy's effectiveness earlier than those methods for many patients, allowing clinicians
Read more
March 15, 2022 Invitae Publishes the 2022 Environmental, Social and Governance Report
Invitae (NYSE: NVTA), a leading medical genetics company, today released its 2022 Environmental, Social and Governance (ESG) Report summarizing the company's performance on key ESG criteria and highlighting its commitment to healthcare for humanity. "Continuing the progress on our ESG efforts is central to our mission and is part of our DNA," said Shelly Guyer, Chief Sustainability Officer at Invitae. "We are dedicated to transparent disclosure, collecting data to enable future goal setting, and sustainable practices to improve healthcare affordability and accessibility to all." The report provides an in-depth review of the progress made in the past year against established frameworks. It also details how Invitae continues to work toward strengthening the policies and procedures that operationalize its commitment to oversight and integration of ESG within strategy and risk management practices. The company recognizes the importance of solid governance, environmental stewardship and
Read more
February 24, 2022 Invitae Reports $460.4 Million in Annual Revenue Driven by 1.17 Million in Billable Volume in 2021
- Annual revenue grew by 65 percent and annual billable volume by 77 percent year over year -
- Full-year 2022 revenue growth guidance of 40 percent to approximately $640 million -
- Guiding to expansion of gross margin throughout 2022 and decreasing cash burn charting path to positive cash flows -
- Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time -  Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and year ended December 31, 2021. "2021 was another year of industry leading growth and the addition of almost 1 million patients onto the Invitae platform, providing further evidence that the Invitae vision and one-of-a-kind testing, digital health and data network are ushering in the era of genomic health management," said Sean George, Ph.D., co-founder and CEO of Invitae. "Looking into 2022, we intend to maintain our focus on driving that shift
Read more
February 16, 2022 Invitae Launches its First CE-IVD Cancer Testing Kits In Europe
- New in-vitro diagnostic kits help patients fight cancer in the EU -  Invitae (NYSE: NVTA), a leading medical genetics company, today announced the availability of FusionPlex Dx ® and LiquidPlex Dx ™ in Europe, part of its industry-leading Anchored Multiplex PCR chemistry in-vitro diagnostic (IVD) products. Invitae is delivering essential high quality innovation for precision oncology in the fight against cancer. With this announcement, Invitae provides the highest quality CE-IVD products to enable European pathologists and oncologists to efficiently provide vital information, in a timely manner, to guide cancer therapy for patients. "This is a major step toward our mission to bring comprehensive genetic information into mainstream medicine," said Vishal Sikri, President of Oncology at Invitae. "Our best in class FusionPlex ® and LiquidPlex ™ tests will enable more patients access to the right cancer therapies at the right time, which is especially critical in Europe where the
Read more
February 10, 2022 Invitae to Announce Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To access the conference call, please register at the link below:
https://conferencingportals.com/event/DqFqYhVe Upon registering, each participant will be provided with call details and a conference ID. Reminders will also be sent to registered participants via email. The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is
Read more
February 3, 2022 Invitae to Present at Upcoming Investor Conferences
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in virtual fireside chats at the following investor conferences: SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022, at 1:00 p.m. Eastern Time. Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 11:10am Eastern Time. A live webcast of each fireside chat may be accessed by visiting the investors section of the company website at ir.invitae.com . Replays of the webcasts will be available shortly after the conclusion of each fireside chat. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more
Read more
February 3, 2022 Invitae Supports the Biden Administration's Advancement of the Cancer Moonshot, Enhanced Recommendations on Genetic Testing for Cancer Treatment
- Recommendations include assessment of eligibility for germline genetic testing for all people diagnosed with cancer - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, applauds the Biden Administration's announcement to reignite the Cancer Moonshot with renewed White House leadership of this effort. As part of this initiative, the newly formed President's Cancer Panel also released a report on Closing the Gaps in Cancer Screening , which includes several important advancements in the use of genetic testing and access to genetic counselors for cancer patients. Cancer remains one of the leading causes of death in the United States, with an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in 2021. More than 13% of cancer patients have a clinically significant germline variant that can be revealed through genetic testing, thereby alerting the patients to their risk for second cancers as well as providing their family members with an
Read more
January 10, 2022 Invitae Reports Preliminary 2021 Revenue of More Than $458 Million and Billable Volume of More Than 1.16 Million
- 64 percent growth year-over-year in revenues
- 76 percent growth year-over-year in billable volumes
- Ended the year with more than 17,500 active healthcare provider accounts
- Active pharma and commercial partnerships expand by 68 percent
- Total patient population is more than 2.5 million with over 62 percent available for data sharing
- Presenting at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:45 a.m. Eastern/6:45 a.m. Pacific - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2021 revenue, billable volume and commercial metrics reporting approximately 64 percent growth in revenue and 76 percent growth in volume, signaling continued momentum into 2022. "We are encouraged by the acceleration of our business in 2021, particularly in light of the direct and indirect impacts on the healthcare system throughout the year," said Sean George, Ph.D., co-founder and
Read more
January 5, 2022 Invitae to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, chief executive officer, will present virtually at the 40 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 9:45 a.m. Eastern Time. The live audio webcast of the presentation may be accessed by visiting the investors section of the company website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the presentation. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com . Contact: ir@invitae.com (628) 213-3369 View original content to download
Read more

DISCLAIMER

The information in the press releases, presentations, webcasts and publications is archival and should be considered accurate only as of its date. We disclaim any obligation to supplement or update the information in these documents, presentations or webcasts.

FORWARD-LOOKING STATEMENTS

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including those risks and uncertainties detailed from time to time in Invitae Corporation’s periodic filings with the Securities and Exchange Commission. Invitae Corporation specifically disclaims any obligation to update any forward-looking statements.

Forward Looking Statements

Investor Toolkit

Feature Presentation

Email Alerts

Sign up to receive Invitae financial information by email.
Email Address: *
I'D LIKE TO RECEIVE EMAILS ABOUT: *




 
Enter the code shown above.

Investor Contact

1400 16th St.
San Francisco, CA, 94103
Email: ir@invitae.com